Y
Yuh Min Chen
Researcher at Taipei Veterans General Hospital
Publications - 231
Citations - 7127
Yuh Min Chen is an academic researcher from Taipei Veterans General Hospital. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 37, co-authored 196 publications receiving 6117 citations. Previous affiliations of Yuh Min Chen include National Health Research Institutes & The Chinese University of Hong Kong.
Papers
More filters
Journal ArticleDOI
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
Vincent A. Miller,Vincent A. Miller,Vera Hirsh,Jacques Cadranel,Yuh Min Chen,Keunchil Park,Sang We Kim,Caicun Zhou,Wu Chou Su,M. Wang,Yan Sun,Dae Seog Heo,Lucio Crinò,Eng Huat Tan,Tsu Yi Chao,Mehdi Shahidi,X.J. Cong,Robert M. Lorence,James Chih-Hsin Yang +18 more
TL;DR: The findings for progression-free survival and response to treatment suggest that afatinib could be of some benefit to patients with advanced lung adenocarcinoma who have failed at least 12 weeks of previous EGFR tyrosine-kinase inhibitor treatment.
Journal ArticleDOI
Mutation in the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor Is a Predictive and Prognostic Factor for Gefitinib Treatment in Patients with Non–Small Cell Lung Cancer
Teh Ying Chou,Chao-Hua Chiu,Ling-Hui Li,Chun-Yen Hsiao,Chin-Yuan Tzen,Kuo-Ting Chang,Yuh Min Chen,Reury-Perng Perng,Shih-Feng Tsai,Chun-Ming Tsai +9 more
TL;DR: Analysis of EG FR tyrosine kinase mutations in lung adenocarcinoma is of clinical significance, as it can permit the customization of treatment with EGFR tyrosin kinase inhibitors.
Journal ArticleDOI
Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial
Yi-Long Wu,Jin Soo Lee,Sumitra Thongprasert,Chong-Jen Yu,Li Zhang,Guia Ladrera,Vichien Srimuninnimit,Virote Sriuranpong,Jennifer Sandoval-Tan,Yunzhong Zhu,Meilin Liao,Caicun Zhou,Hongming Pan,V. Lee,Yuh Min Chen,Yuh Min Chen,Yan Sun,Benjamin Margono,Fatima Fuerte,Gee-Chen Chang,Kasan Seetalarom,Jie Wang,Ashley Cheng,Elisna Syahruddin,Xiaoping Qian,James Chung-Man Ho,Johan Kurnianda,Hsingjin Eugene Liu,Kate Jin,Matt Truman,Ilze Bara,Tony Mok +31 more
TL;DR: Intercalated chemotherapy and erlotinib is a viable first-line option for patients with non-small-cell lung cancer with EGFR mutation-positive disease or selected patients with unknown EGFR mutations status.
Journal ArticleDOI
Association between simple anthropometric indices and cardiovascular risk factors.
TL;DR: The association of central or general obesity and metabolic syndrome varied with gender, and the useful anthropometric predictors for cardiovascular risk factors were BMI and WC for men, and WC and WHR for women.
Journal ArticleDOI
Randomized, Placebo-Controlled, Phase II Study of Sequential Erlotinib and Chemotherapy As First-Line Treatment for Advanced Non–Small-Cell Lung Cancer
Tony Mok,Yi-Long Wu,Chong-Jen Yu,Caicun Zhou,Yuh Min Chen,Li Zhang,Jorge Ignacio,Meilin Liao,Vichien Srimuninnimit,Michael Boyer,Marina Chua-Tan,Virote Sriuranpong,Aru W Sudoyo,Kate Jin,Michael R. Johnston,Winsome Chui,Jin Soo Lee +16 more
TL;DR: In this article, the authors investigated whether sequential administration of erlotinib and chemotherapy improves clinical outcomes versus chemotherapy alone in unselected, chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC).